ArticleTechnology in cancer research & treatment
The Predictive Value of Extracellular Volume Fraction Derived from Enhanced CT Combined with Systemic Immune-Inflammation Index for Tumor Budding in Rectal Cancer.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionTo explore the value of enhanced computed tomography (CT) -derived extracellular volume (ECV) combined with systemic immune-inflammation index (SII) in predicting tumor budding (TB) grading of rectal cancer.Materials and MethodsThe clinical and imaging data of 177 rectal cancer patients were retrospectively analyzed, and we divided them into a low-grade and medium-high group according to pathological TB count. ECV and SII values between the two groups were compared. Intra-class correlation coefficient (ICC) was used to detect the consistency of measurements among observers. Binary logistic regression was used to analyze the correlations between variables and TB grading of rectal cancer. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic efficiency of statistically significant parameters and their combination. Area under the curve (AUC), its 95% confidence interval, and the corresponding Youden index, sensitivity, and specificity were calculated.ResultsAmong the 177 rectal cancer patients, 108 were low-grade and 69 were medium-high grade. ECV values measured by two physicians showed good consistency (ICC = 0.98). ECV value of low-grade (21.76% ± 4.89%) was lower than that of medium-high grade TB group (27.91% ± 4.77%) (P < .001). SII value was lower in low-grade group (492.14 ± 239.56) than in medium-high grade TB group (825.02 ± 529.38). In the multivariate analysis, ECV value [odds ratio (OR): 1.339 (95% CI: 1.194-1.502)] and SII value [OR: 1.004 (95% CI: 1.002-1.005)] were independent risk factors for predicting TB grading. In the training set, AUCs of ECV, SII, and their combination in evaluating TB grading of rectal cancer were 0.838 (95% CI: 0.760-0.905), 0.755 (95% CI: 0.663-0.829), and 0.889 (95% CI: 0.832-0.943), respectively. In the test set, the corresponding AUCs were 0.741 (95% CI: 0.626-0.870), 0.716 (95% CI: 0.554-0.849), and 0.815 (95% CI: 0.711-0.913). Decision curve analysis (DCA) showed that the combination had higher clinical value than using ECV or SII alone.ConclusionThe combination of ECV and SII can non-invasively evaluate TB grading of rectal cancer before surgery, potentially providing a reference for preoperative risk stratification as a decision-support tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.